Avanir Pharmaceuticals, Inc.
) recently received a positive opinion from the Committee for
Medicinal Products for Human Use (CHMP) for Nuedexta.
Nuedexta is under review in the EU for the treatment of
patients suffering from pseudobulbar affect (PBA). The committee
has also recommended approval for two dosage strengths - 20/10 mg
and 30/10 mg capsules.
In Nov 2011, Avanir's Marketing Authorization Application
(MAA) for Nuedexta was accepted by the European Medicines Agency
(EMA). The application was based on controlled phase III studies
of Nuedexta in patients with PBA, plus data from longer-term
We note that Nuedexta is approved in the US where it is the
first and only Food and Drug Administration (FDA)-approved
treatment for PBA. Nuedexta was launched in the US in Jan 2011.
Net Nuedexta revenues grew 20% sequentially to $14.9 million in
the first quarter of 2013 ending on Dec 2012.
With the CHMP issuing a positive opinion, we expect Nuedexta
to gain EU approval shortly.
We are encouraged by Avanir's progress with its pipeline. In
Feb 2013, Avanir completed the first of a two-stage
pharmacokinetic study with AVP-786. The study assessed the
candidate's single and multiple dose pharmacokinetics.
Meanwhile, AVP-923 is being studied for four indications,
namely, agitation in Alzheimer's disease (phase II ongoing),
central neuropathic pain in multiple sclerosis (phase II
ongoing), diabetic peripheral neuropathic pain (phase III
completed) and levodopa-induced-dyskinesia in Parkinson's
Avanir currently carries a Zacks Rank #4 (Sell). Companies
Catalyst Pharmaceutical Partners Inc.
) carry a Zacks Rank #1 (Strong Buy).
Onyx Pharmaceuticals, Inc.
) is also well positioned with Zacks Rank #2 (Buy).
AVANIR PHARM (AVNR): Free Stock Analysis
CATALYST PHARMA (CPRX): Free Stock Analysis
ONYX PHARMA INC (ONXX): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.